Endometrial Serous Adenocarcinoma — Variants & evidence

Endometrial Serous Adenocarcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

5 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–5 of 5 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CCNE1 Amplification1
Fadraciclib + TaselisibCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID10181 Analysis of 5 uterine serous carcinoma (USC) primary cell lines in vitro indicated enhanced sensitivity to CDK2/9 inhibitor CYC065 in cell lines overexpressing cyclin E1 (CCNE1) in comparison to low C… (full text at CIViC) PMID 27351214 · Cocco et al., 2016 · Open in CIViC	civic
ERBB2 Amplification3
(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID1096 In a study of 27 African American and caucasian patients, endometrial adenocarcinoma samples were assessed for HER2 via IHC staining, and association studies were performed using corresponding patient… (full text at CIViC) PMID 15746676 · Santin et al., 2005 · Open in CIViC	civic
Trastuzumab	Predictive	C	Supports Sensitivity Response	4	accepted	EID1097 HER2 expression in uterine serous papillary carcinoma (USPC) is thought to be associated with poor prognosis and may act as a targetable driver mutation in this cancer. HER2 overexpression in USPC is… (full text at CIViC) PMID 18555254 · Santin et al., 2008 · Open in CIViC	civic
Carboplatin/Paclitaxel Regimen + TrastuzumabCombination	Predictive	B	Supports Sensitivity Response	4	submitted
ERBB2 Overexpression1
Carboplatin + Paclitaxel + TrastuzumabCombination	Predictive	B	Supports Sensitivity Response	4	submitted	EID7386 In a randomized phase 2 trial, patients who have uterine serous carcinoma that overexpress erbb2 were allocated carboplatin-paclitaxed with or without trastuzumab. Median progression-free survival was… (full text at CIViC) PMID 29584549 · Fader et al., 2018 · Open in CIViC	civic

Data updated 11 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.